

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Division of Public and Behavioral Health

Helping people. It's who we are and what we do.



Interim 2019 Novel Coronavirus (2019 nCoV) assessment information: Evaluating persons with fever and acute respiratory illness

- Obtain a detailed travel history on ALL patients being evaluated for fever and acute respiratory illness.
- Use the assessment criteria below to determine if 2019 nCoV should be included in the differential diagnosis.

Name:			DOB		Interview date:	
Address					Phone	
Assessment Criteria	Yes	No	Comments			
A) Did/Does the patient have a fever? (Fever ma		INO	Fever onset date:/_	1		
not be present in some patients; use clinical			Highest measured temper	/	□ °F □ °C	
judgment to guide testing.)			☐ Check if SUBJECTIVE fe			
B) Does the patient have symptoms of lower			Symptom onset date:			
respiratory illness (LRI) (e.g., cough, difficulty			' '	□ Cough □ Sore throat □ Difficulty breathing		
breathing)?			_	Other Symptoms (list):		
C) In the 14 days before symptom onset, did the			Dates in Wuhan: /	/ +) / /	
				Return to /Arrival in US		
patient: i. Travel from Wuhan City, China*?			Other locations visited in 14 days before symptom onset:			
OR			Other locations visited in	14 days ber	ore symptom onset:	
			D-1	40 - C - V DI II	//	
ii. Have close contact with a person who is under			Dates of contact with 2019nCoV PUI/lab-confirmed case:			
investigation (PUI) for 2019-nCoV while that			PUI/lab-confirmed case name (if known):			
person was ill?			PUI/lab-confirmed case r	name (if knov	wn):	
OR			 			
iii. Have close contact with a lab-confirmed			Nature of contact: □ Family/Household □ Coworker			
2019-nCoV patient while that person was ill?			□ Healthcare worker □ Travel □ Other:			
			Comments:			
Suspect 2019-nCoV if you answered YES to					tion but there is a high index of	
A and B and (Ci or Cii), OR (A or B) and Ciii			clinical suspicion, contact LHA.			
 □ Ensure that the patient is masked and isolated □ Ensure that healthcare personnel entering the face shield). • Please note: Airborne precautions inclu □ Notify your healthcare facility's infection control □ Perform any clinically indicated respiratory and □ Respiratory testing performed (indicate results 	room use con ide use of NIO ol personnel. I other diagno	tact, dro	plet, AND airborne precaution		ING eye protection (e.g., goggles or	
- Respiratory testing performed (indicate results	ii kilowiij.					
□ Rapid Influenza: □ A □ B	□ Neg □ Pos □ Pending □ Not Done				ally relevant testing:	
□ Rapid Strep	□ Neg □ Pos □ Pending □ Not Done				/ □ Not Done □ Pending □ Normal	
□ Viral Respiratory Panel	□ Neg □ Pos □ Pending □ Not Done			□ Abnorma	l:	
□ Pneumonia	□ Neg □ Pos □ Pending □ Not Done			Other:		
□ Legionella	□ Neg □ Pos □ Pending □ Not Done					
□ Other:	□ Neg □ Pos □ Pending □ Not Done			Other:		
□ Other:	□ Neg □ Pos	🗆 Pendi	ng □ Not Done			
☐ Call your local health authority (LHA) with the a and the LHA is not available, call the Nevada D	ivision of Pub	ic & Beh	avioral Health: (775) 400-03	333).		
☐ If instructed by your local health department, c collection guidance on Public Health Laborator				lle East Resp	iratory Syndrome (MERS) specimen	
□ NP swab (synthetic swab in 2-3 ml viral transport media)			□ Sputum (in steri	☐ Sputum (in sterile cup)		
☐ OP swab (synthetic swab in 2-3 ml viral transport media)			☐ Urine (in sterile cup)			
☐ Serum (5-10 ml in serum separator tube)			☐ Stool, if possible (in sterile cup)			
				, 12		